One of the recent advances in 21st century medicine is the emergence of gene therapies drugs that affect the basic biology of genetic disease. The field has seen some notable setbacks in the past but in recent years has exploded as decades of basic science have been successfully translated into the most complex biologics ever constructed leading to regulatory approval of several gene therapy products in oncology hematology neurology and ophthalmology indications. These drugs are at the apex of biological manufacturing complexity and have the potential to be disease modifying or even curative. Evidence-based and innovative quantitative clinical development and lifecycle management strategies will be required as fixtures in the development for these unique drugs in order to reach patients in need. Development of Gene Therapies: Strategic Scientific and Regulatory Considerations is an unparalleled summary of the current scientific statistical developmental and regulatory aspects of gene therapies which is fast becoming a core area of the biopharmaceutical industry. This edited volume provides a systematic description of core development topics in gene therapies through 19 peer-reviewed chapters written by subject matter experts in the field. This edited volume is an invaluable resource for business leaders and investors hoping to understand the scientific principles and strategy of a company they may potentially invest in; the family members of someone affected by a genetic disease who wish to understand better how these therapies work and what they might expect as a treatment for a loved one; academic professionals who want to learn and teach incoming medical public health or business students; and seasoned drug developers who wish to learn more about the about the cutting edge of biopharmaceutical drug development. Key Features: Provides a thorough background on the scientific manufacturing and translational concepts and competencies for gene therapies. Covers important strategic aspects of the gene therapy industry thereby helping investors drug developers and regulators gain a better appreciation of the potential value of gene therapies. Expounds on many existing and emerging state-of-the art scientific and technological advances as well as ethical pharmacovigilance and regulatory considerations for gene therapy product development. Presents several case studies of successful development of gene therapies including two of the most remarkable FDA-approved gene therapy products: Zolgensma and Luxturna. Provides perspectives and forward-looking statements on the future of gene therapies in neurological in utero and ultra-rare indications. | Development of Gene Therapies Strategic Scientific Regulatory and Access Considerations
One of the recent advances in 21st century medicine is the emergence of gene therapies drugs that affect the basic biology of genetic disease. The field has seen some notable setbacks in the past but in recent years has exploded as decades of basic science have been successfully translated into the most complex biologics ever constructed leading to regulatory approval of several gene therapy products in oncology hematology neurology and ophthalmology indications. These drugs are at the apex of biological manufacturing complexity and have the potential to be disease modifying or even curative. Evidence-based and innovative quantitative clinical development and lifecycle management strategies will be required as fixtures in the development for these unique drugs in order to reach patients in need. Development of Gene Therapies: Strategic Scientific and Regulatory Considerations is an unparalleled summary of the current scientific statistical developmental and regulatory aspects of gene therapies which is fast becoming a core area of the biopharmaceutical industry. This edited volume provides a systematic description of core development topics in gene therapies through 19 peer-reviewed chapters written by subject matter experts in the field. This edited volume is an invaluable resource for business leaders and investors hoping to understand the scientific principles and strategy of a company they may potentially invest in; the family members of someone affected by a genetic disease who wish to understand better how these therapies work and what they might expect as a treatment for a loved one; academic professionals who want to learn and teach incoming medical public health or business students; and seasoned drug developers who wish to learn more about the about the cutting edge of biopharmaceutical drug development. Key Features: Provides a thorough background on the scientific manufacturing and translational concepts and competencies for gene therapies. Covers important strategic aspects of the gene therapy industry thereby helping investors drug developers and regulators gain a better appreciation of the potential value of gene therapies. Expounds on many existing and emerging state-of-the art scientific and technological advances as well as ethical pharmacovigilance and regulatory considerations for gene therapy product development. Presents several case studies of successful development of gene therapies including two of the most remarkable FDA-approved gene therapy products: Zolgensma and Luxturna. Provides perspectives and forward-looking statements on the future of gene therapies in neurological in utero and ultra-rare indications. | Development of Gene Therapies Strategic Scientific Regulatory and Access Considerations
Sellers offer a range of delivery options, so you can choose the one thatâs most convenient for you. Many sellers offer free delivery. You can always find the postage cost and estimated delivery date in a sellerâs listing. You'll then be able to see a full list of delivery options during checkout. These can include: Express delivery, Standard delivery, Economy delivery, Click & Collect, Free local collection from seller.
Your options for returning an item vary depending on what you want to return, why you want to return it, and the seller's return policy. If the item is damaged or doesn't match the listing description, you can return it even if the seller's returns policy says they don't accept returns. If you've changed your mind and no longer want an item, you can still request a return, but the seller doesn't have to accept it. If the buyer changes their mind about a purchase and wants to return an item, they may need to pay return postage costs, depending on the seller's return policy. Sellers can provide a return postage address and additional return postage information for the buyer. Sellers pay for return postage if there's a problem with the item. For example, if the item doesn't match the listing description, is damaged or defective or is counterfeit. By law, customers in the European Union also have the right to cancel the purchase of an item within 14 days beginning from the day you receive, or a third party indicated by you (other than the carrier) receives, the last good ordered by you (if delivered separately). This applies to all products except for digital items (e.g. Digital Music) that are provided immediately to you with your acknowledgement, and other items such as video, DVD, audio, video games, Sex and Sensuality products and software products where the item has been unsealed.
Sellers have to offer a refund for certain items only if they are faulty, such as: Personalised items and custom-made items, Perishable items, Newspapers and magazines, Unwrapped CDs DVDs and computer software. If you used your PayPal balance or bank account to fund the original payment, the refunded money will go back to your PayPal account balance. If you used a credit or debit card to fund the original payment, the refunded money will go back to your card. The seller will effect the refund within three working days but it may take up to 30 days for Paypal to process the transfer. For payments funded partially by a card and partially by your balance/bank, the money taken from your card will go back to your card and the remainder will return to your PayPal balance.